AbbVie Cash on Hand 2010-2024 | ABBV | MacroTrends

AbbVie Cash on Hand 2010-2024 | ABBV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbbVie cash on hand for the quarter ending December 31, 2024 was $5.555B, a 56.66% decline year-over-year.

AbbVie cash on hand for 2024 was $5.555B, a 56.66% decline from 2023.
AbbVie cash on hand for 2023 was $12.816B, a 38.87% increase from 2022.
AbbVie cash on hand for 2022 was $9.229B, a 6.11% decline from 2021.

AbbVie Cash on Hand 2010-2024 | ABBV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbbVie cash on hand for 2024 was $5.555B, a 56.66% decline from 2023.
AbbVie cash on hand for 2023 was $12.816B, a 38.87% increase from 2022.
AbbVie cash on hand for 2022 was $9.229B, a 6.11% decline from 2021.

Related Stocks
Company Name	Market Cap
Eli Lilly (LLY)	$827.9B
Johnson & Johnson (JNJ)	$384.4B
Novo Nordisk (NVO)	$375.8B
Roche Holding AG (RHHBY)	$262.5B
Merck (MRK)	$221.8B
Novartis AG (NVS)	$219.3B
Pfizer (PFE)	$146.8B
Sanofi (SNY)	$137.4B
Bayer (BAYRY)	$22.6B
Innoviva (INVA)	$1.1B